CatalYm GmbH

Meet our CMO, Eugen Leo, MD, PhD, MBA, and Solid Tumor Program Co-Heads, Felix Lichtenegger, MD, PhD, and Avital Barak MD. PhD., at the upcoming ESMO - European Society for Medical Oncology Congress 2024 starting on Friday in Barcelona. Eugen, Felix and Avital are looking forward to connecting with other #oncology experts and discussing the latest data in the field of #SolidTumor treatment. This includes new insights in the role of GDF-15 in cancer therapy resistance and treatment-related side effects, such as cachexia, and how to leverage this knowledge to improve clinical outcomes and patients’ quality of life.   At CatalYm, we are pioneering a GDF-15 neutralizing approach with our lead antibody candidate, visugromab, aiming to counteract resistance and improve the efficacy and tolerability of current standard-of-care treatments.   To learn more about our company and the ongoing clinical Phase 2 evaluation of visugromab in several solid tumor indications, please visit: https://www.catalym.com/     #ESMO24

#Catalym at World Conference on Lung Cancer 2024 #WCLC24 in San Diego! In the early hours today we conducted our US Lung cancer program Steering Committee session with #RoyHerbst and other leading US lung cancer specialists, with presentations by Felix Lichtenegger, our VP Clinical Development and Eugen Leo, our CMO. Data updates on the latest efficacy and safety data of our #GDF15 blocking antibody visugromab were provided and our future #GDFATHER lung cancer program in 1L and 2L NSCLC was reviewed. The trials are expected to start in early 2025 and will evaluate the efficacy and safety of #visugromab in non-squamous NSCLC. And - more good news on visugromab data will come soon! Stay tuned! #Catalym #visugromab #GDF15 #WCLC24 #create_a_cure_for_metastatic_disease

🌟 Translating science into a novel treatment approach 🌟   Based on our comprehensive insights into the underlying biology of GDF-15-mediated resistance to cancer therapies, we at CatalYm developed our clinical lead candidate visugromab, an anti-GDF-15 antibody, to tackle this major limitation in the treatment of #SolidTumors.   Watch the video below, where our Chief Scientific Officer, Christine Schuberth-Wagner, explains how visugromab’s GDF-15 neutralizing effect demonstrates a multi-layered mechanism of action to counteract immunoevasion-based cancer resistance and enhance the efficacy and tolerability of a range of standard-of-care regimens. In light of the promising Phase 2 data updates in several high-need solid tumor indications at #ASCO this year, we believe that visugromab has the potential to become a new backbone component in the cancer therapy landscape.   Stay tuned here on LinkedIn to get the latest news around visugromab, including the ongoing Phase 2 trial in hard-to-treat late- to last-line CPI r/r #SolidTumor patients and the planned initiation of additional studies in early-line settings.   #CancerTherapy #CancerResistance 

A very warm #welcome to Avital Barak MD. PhD., who joins the CatalYm team as Solid Tumor Program Co-Lead (together with Felix Lichtenegger). Avital is a physician-scientist and internal medicine specialist. She completed a PhD in tumor Immunology at the Weizmann Institute of Science and held multiple senior positions in pharmaceutical industry and Biotech, leading clinical development of various innovative compounds. Avital will further broaden our dedicated Clinical Development experience and will be the medical indication lead for one of our solid tumor programs. Find more information about our dedicated mission to bring #visugromab and #GDF-15 neutralization as novel treatment option to cancer patients in need on our website: www.catalym.com Find more information about our mission to translate the therapeutic potential of GDF-15 neutralization into meaningful clinical responses for #cancer patients on our website: www.catalym.com #CatalYm #visugromab #GDF-15 #oncology

Don’t miss the chance to speak with our CMO, Eugen Leo, MD, PhD, MBA, and our VP of Clinical Development, Felix Lichtenegger, MD, PhD, at the upcoming International Association for the Study of Lung Cancer’s #WCLC24 and discover how we at CatalYm are leveraging our novel GDF-15 neutralization approach to counteract resistance and improve outcomes in various #SolidTumor types. This includes non-small cell lung cancer (#NSCLC), one of the indications investigated in our ongoing Phase 2 trial with our anti-GDF-15 antibody lead candidate, visugromab.   Visit https://lnkd.in/d5WdA4xj to find out where you can find us next!

🌟 Discover the science behind innovation 🌟   We at CatalYm are at the forefront of pioneering a novel cancer therapy approach, leveraging our scientific insights into the newly identified role of GDF-15 as a key regulator of tumor resistance.   In the short video below, our Chief Scientific Officer, Christine Schuberth-Wagner, delves into GDF-15’s diverse mechanisms of action in regulating anti-tumor immune responses and driving treatment-induced side effects such as anorexia, nausea, and emesis. She emphasizes the potential of neutralizing this immunosuppressive cytokine as a promising strategy to combat treatment resistance and enhance the clinical outcomes and tolerability of various standard-of-care regimens.   Curious to learn more about the science behind our innovative treatment strategy and our clinical lead candidate, visugromab, a GDF-15-targeting antibody? Visit us at www.catalym.com.   Stay connected with us on LinkedIn for the latest updates on our lead program, study data, and the next steps on our clinical development journey! #CancerTherapy #GDF15 #Immunotherapy #ClinicalDevelopment 

Thank you Thorsten Ross for the great representation of CatalYm at the recent Federation of American Societies for Experimental Biology (FASEB)'s Scientific Research Conference!

Great news from CatalYm: we have successfully completed an oversubscribed $150 million Series D #financing to advance our lead program #visugromab into randomized Phase 2b clinical trials. This investment will expand visugromab’s late-stage clinical development into earlier lines of treatment including checkpoint naïve and second-line refractory settings in select #SolidTumor indications. We extend a warm welcome to our new investors: Canaan, Bioqube Ventures, Omega Funds, Forbion Growth Fund and Gilde Healthcare Partners. Together with support from our participating existing investors JEITO, Brandon Capital, Novartis Venture Fund and Vesalius Biocapital III  the funding highlights the potential of visugromab to bring benefit to cancer patients and also values the novel approach of neutralizing GDF-15, a key resistance factor to anti-cancer therapies. Visugromab is a humanized monoclonal antibody targeting GDF-15, a key regulator of immune resistance to #cancer therapies. Our lead candidate has shown impressive results in a recent Phase 1/2a data update presented at #ASCO2024. The results demonstrated that the combination of visugromab and the PD-1 inhibitor nivolumab achieves deep and durable anti-tumor activity, including complete responses, in patients with anti-PD-(L)1 relapsed/refractory solid tumors. Along with the financing, Colleen Feriod Cuffaro, Partner at Canaan, Jon Edwards, Managing Partner at Bioqube Ventures, and Otello Stampacchia, Managing Director and Founder at Omega Funds, will join our Board of Directors, and Stefan Luzi, PhD, Partner at Gilde joins as an Observer. As we enter this next stage of corporate growth, we remain committed to our mission of breaking immunosuppressive barriers and establishing a new benchmark in cancer care. For more details on the financing, visit: https://lnkd.in/dBfHK4sU

Our VP Preclinical Development & Translation Strategy, Thorsten Ross, is looking forward to his presentation next week at the Federation of American Societies for Experimental Biology (FASEB)’s Scientific Research Conference focusing on the TGF-β Superfamily. In his talk on July 22, he will outline our latest findings demonstrating that GDF-15, a member of this cytokine family, is a central mediator of #cancer treatment resistance and toxicity in platinum-based #chemotherapy, which is commonly used alongside PD-1 checkpoint inhibitors in the first-line treatment of advanced #NSCLC. Our preclinical findings showcase the potential of our lead antibody candidate visugromab, a first-in-class GDF-15-blocking antibody, to enhance responses and tolerability of standard-of-care chemoimmunotherapy. Find the full agenda details here https://bit.ly/45Z5aD1 and learn more about our novel strategy to counteract resistance and improve #SolidTumor #patient outcomes at www.catalym.com #TGFSRC

This weekend, the Coordinating Investigator of our "GDFATHER" Phase 1/2a trial, Prof. Ignacio Melero, MD, PhD, presented compelling new follow-up data at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results highlight that visugromab+nivolumab treatment achieves remarkable deep and durable anti-tumoral activity including multiple complete responses in late- to last-line patients with metastatic non-sq NSCLC, Urothelial cancer and HCC. Currently, median duration of response is surpassing 15 months for NSCLC and 14 months for UC cohorts, with 77% of all responses still ongoing. Remarkably, 53% of patients experiencing a response on study achieved a RECIST 1.1 response level not reached with their initial checkpoint inhibitor treatment in 1L/2L. 75% of the complete responses in non-sq NSCLC and UC had not achieved a CR on any prior systemic treatment before, all ongoing as of now. Patients that entered the trial had to be truly anti-PD-1/PD-L1 relapsed/refractory as per strict criteria. Given the clinical and preclinical data to date, we are convinced that targeting GDF-15 has the potential to break a critical therapeutic resistance pathway and establish a new benchmark in checkpoint inhibition potentiation. We will now take this promising therapeutic concept into 1L and 2L treatment of multiple solid tumor types to maximize potential benefit to patients in need suffering from metastatic solid tumors with no curative option so far. Read more about the full data, the main differentiators of this approach, future development plans, and the potential beneficial impact for patients here: https://lnkd.in/dYwxKq7d